Biotech
Biotech Calendar: Upcoming FDA Dates
Labopharm(DDSS)
Drug/indication: Trazodone Contramid for depression
FDA approval decision date: Feb. 11, 2010
Drug/indication: acetavance for pain
FDA approval decision date: Feb. 12, 2010 Gilead Sciences(GILD)
Drug/indication: Cayston for cystic fibrosis
FDA approval decision date: Feb. 13, 2010 Salix Pharmaceuticals(SLXP)
Drug/indication: Xifaxan for hepatic encephalopathy
FDA advisory committee meeting: February 2010
FDA approval decision date: March 24, 2010 Shire Pharmaceuticals(SHPGY)
Drug/indication: velaglucerase for Gaucher's disease
FDA approval decision date: Feb. 28, 2010 Amylin Pharmaceuticals(AMLN)
Drug/indication: Exenatide LAR for diabetes
FDA approval decision date: March 5, 2010 Clinical Data(CLDA)
Drug/indication: vilazodone for depression
Filing for FDA approval: First quarter 2010 Somaxon Pharmaceuticals(SOMX)
Drug/indication: Silenor for insomnia
Outcome of FDA meeting to discuss complete response letter: First quarter 2010 Cell Therapeutics(CTIC)
Drug/indication: pixantrone for non-Hodgkin's lymphoma
FDA approval decision date: April 23, 2010 Eli Lilly(LLY)
Drug/indication: Erbitux for first-line non-small cell lung cancer
Filing for FDA approval: First quarter 2010 Dendreon(DNDN)
Drug/indication: Provenge for prostate cancer
FDA approval decision date: May 1, 2010 Avanir Pharmaceuticals(AVNR)
Drug/indication: Zenvia for pseudobulbar effect
Filing for FDA approval: Second quarter 2010 Alkermes(ALKS)
Drug/indication: Vivitrol for opioid addiction
Filing for FDA approval: First half 2010 InterMune(ITMN)
Drug/indication: pirfenidone for idiopathic pulmonary fibrosis
FDA advisory committee meeting: First half 2010 FDA approval decision date: Second half 2010 Human Genome Sciences(HGSI)
Drug/indication: Benlysta for lupus
Filing for FDA approval: First half 2010 Orexigen Therapeutics(OREX)
Drug/indication: Contrave for obesity
Filing for FDA approval: First half 2010 -- Reported by Adam Feuerstein in Boston
TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,393.45 | 1,310.33 | 2,827.34 | 14.60 |
Oil *
98.16
|
|
DOWN
26.41 |
DOWN
2.99 |
DOWN
10.02 |
DOWN
1.21 |
10 Yr
1.46%
SPDR Gold
151.62
|
|
-0.21%
|
-0.23%
|
-0.35%
|
-7.65%
|
Data delayed 20 minutes |
Connect with TheStreet